| Trial ID: | L7071 |
| Source ID: | NCT05780905
|
| Associated Drug: |
Semaglutide Auto-Injector
|
| Title: |
Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes
|
| Acronym: |
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2|Stroke (CVA) or Transient Ischemic Attack
|
| Interventions: |
DRUG: Semaglutide Auto-Injector|OTHER: Placebo
|
| Outcome Measures: |
Primary: Intracranial blood flow (IBF), measured as total length and number of distal vessels, Approximately 12 Months|bloodbrain barrier Ktrans, measured by dynamic contrast-enhanced MRI, Approximately 12 Months | Secondary: Inflammatory markers, hsCRP, interleukin-6 and tumor necrosis factor -a, Approximately 12 Months
|
| Sponsor/Collaborators: |
Sponsor: University of Washington | Collaborators: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
50
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SCREENING
|
| Start Date: |
2024-01-11
|
| Completion Date: |
2026-12-31
|
| Results First Posted: |
|
| Last Update Posted: |
2024-06-05
|
| Locations: |
University of Washington - Harborview Medical Center, Seattle, Washington, 98104, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT05780905
|
